Cannabis extracts are a “highly effective” therapy to treat adult patients with drug resistant epilepsy, the study concluded.
Archives: News Releases
Since 1992, every Thursday and when breaking news warrants, NORML | The NORML Foundation have been issuing weekly press releases for marijuana law supporters and the media.
NORML’s News Releases archives goes back to 1996 and serves as a valuable tool to alert citizens about cannabis-related news and legislation as well as a research tool for reviewing a chronology of marijuana law reform.
Authors reported that 79 percent of patients surveyed acknowledged either ceasing or reducing their use of pain medications following their initiation of medical cannabis.
Investigators reported that patients averaged a nearly two-point decrease in their pain scores (on an 11-point scale) during the trial period.
Findings showed that the daily use of oral hemp-derived CBD extracts consistently resulted in positive urine IA [immunoassay] screening results.
“Cannabis use appeared to significantly reduce the number of patients that persistently used opioids greater than 90 days after [surgery] from 9.5 percent to 1.4 percent,” investigators concluded.
The study is among the first ever to assess cannabis’ influence on clinical outcomes in adult patients with ASD.
“Patients in the investigational group experienced a significantly greater reduction in sleep disturbances, and in agitation and aggression,” researchers concluded.
The study’s authors concluded, “Medical cannabis is associated with therapeutic effects on pain in older adults with an acceptable safety profile.”